Ms. Willey joined the board, representing the Series Seed investors, in June 2021. She has been in the business of commercializing university research results for over 35 years. Ms. Wiley currently serves as an independent director of Vascugen, a biotech company advancing cell replacement therapy and also serves on the boards of Periodic, Diagnotes, and IU Ventures where she manages IU Ventures’ three venture funds. Ms. Wiley has served as a senior executive for business development for Cold Spring Harbor Laboratory, Mount Sinai School of Medicine in NYC and was the founding Chief Executive of Cambridge Enterprise Ltd in Cambridge England. Earlier in her career, she led technology transfer at Purdue Research Foundation and was engaged in the founding of Cook Biotech, served as part of the early business team at Endocyte and co-founded ARCH Development Partners, a venture fund affiliated with the University of Chicago. Ms. Wiley currently serves on the scientific advisory committee for the Frankel Innovation Initiative at the University of Michigan Medical School and is an advisor to a few select translation organizations including Oncode Institute for cancer research in the Netherlands.